BIODESIX INCBDSXEarnings & Financial Report
Biodesix Inc is a molecular diagnostics enterprise specializing in developing and commercializing innovative blood-based testing solutions for oncology and infectious disease fields. It primarily serves healthcare providers, biopharmaceutical partners and patients across North America, with core business covering personalized medicine products that support clinical decision making.
BDSX Q4 FY2025 Key Financial Metrics
Revenue
$28.8M
Gross Profit
N/A
Operating Profit
$-2.0M
Net Profit
$-4.0M
Gross Margin
N/A
Operating Margin
-6.8%
Net Margin
-13.8%
YoY Growth
40.8%
EPS
$-3.35
BIODESIX INC Q4 FY2025 Financial Summary
BIODESIX INC reported revenue of $28.8M (up 40.8% YoY) for Q4 FY2025, with a net profit of $-4.0M (up 51.8% YoY) (-13.8% margin).
Key Financial Metrics
| Total Revenue | $28.8M |
|---|---|
| Net Profit | $-4.0M |
| Gross Margin | N/A |
| Operating Margin | -6.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
BIODESIX INC Q4 FY2025 revenue of $28.8M breaks down across 2 segments, led by Diagnostic Tests at $25.1M (87.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Diagnostic Tests | $25.1M | 87.5% |
| Development Services | $3.6M | 12.5% |
BIODESIX INC Revenue by Segment — Quarterly Trend
BIODESIX INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Diagnostic Tests and Development Services) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Diagnostic Tests | $25.1M | $19.8M | $17.9M | $16.3M |
| Development Services | $3.6M | $1.9M | $2.1M | $1.6M |
BIODESIX INC Annual Revenue by Year
BIODESIX INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $88.5M).
BIODESIX INC Quarterly Revenue & Net Profit History
BIODESIX INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $28.8M | +40.8% | $-4.0M | -13.8% |
| Q3 FY2025 | $21.8M | +19.9% | $-8.7M | -40.0% |
| Q2 FY2025 | $20.0M | +11.7% | $-11.5M | -57.3% |
| Q1 FY2025 | $18.0M | +21.2% | $-11.1M | -61.8% |
| Q4 FY2024 | $20.4M | +39.3% | $-8.3M | -40.4% |
| Q3 FY2024 | $18.2M | +34.5% | $-10.3M | -56.5% |
| Q2 FY2024 | $17.9M | +51.0% | $-10.8M | -60.3% |
| Q1 FY2024 | $14.8M | +63.6% | $-13.6M | -91.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.8M | $17.9M | $18.2M | $20.4M | $18.0M | $20.0M | $21.8M | $28.8M |
| YoY Growth | 63.6% | 51.0% | 34.5% | 39.3% | 21.2% | 11.7% | 19.9% | 40.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $87.2M | $115.8M | $102.7M | $97.2M | $86.2M | $87.7M | $88.7M | $87.5M |
| Liabilities | $92.7M | $79.6M | $74.9M | $76.4M | $75.2M | $86.6M | $90.4M | $89.9M |
| Equity | $-5.5M | $36.3M | $27.9M | $20.9M | $11.1M | $1.1M | $-1.7M | $-2.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.3M | $-18.6M | $-10.7M | $-4.1M | $-8.6M | $-6.6M | $-8.9M | $778000 |